SOURCE: Medivation

Medivation

June 17, 2015 07:00 ET

Medivation and Astellas Announce Enrollment of the First Patients in Advanced Prostate Cancer Outcomes Registry

TRUMPET Study Seeks Insights to Better Understand Treatment Regimens, Quality of Life Outcomes for Patients Living With Castration-Resistant Prostate Cancer and Their Caregivers

SAN FRANCISCO, CA and NORTHBROOK, IL--(Marketwired - Jun 17, 2015) -  Medivation (NASDAQ: MDVN) and Astellas announced today that the first patients have been enrolled in TRUMPET (Treatment Registry for Outcomes in CRPC Patients), a prospective observational patient registry designed to better understand the unique needs and treatment patterns for patients with castration-resistant prostate cancer (CRPC). The registry will enroll and evaluate 2,000 patients diagnosed with CRPC from urology and oncology sites across the United States. The study will also collect data from the primary caregivers of patients, including spouses, family members and/or friends.

"While there have been many treatment advances in prostate cancer over the past few years, there is still a great deal for us to learn. The insights from TRUMPET can directly impact our research and increase our understanding of important treatment considerations," said Jeffrey Bloss, M.D., senior vice president, Astellas Pharma Global Development, Inc. "This registry provides an important building block to support our commitment to providing effective, evidence-based cancer care for patients and their caregivers."

TRUMPET will follow patients with CRPC and participating caregivers for up to six years to gather information about the management of the disease, including patterns of care, treatment decisions and settings, and physician referral patterns. The registry will also track information about patient health-related quality of life outcomes, work productivity and treatment satisfaction, as well as caregiver health-related quality of life outcomes associated with managing a patient with CRPC.

"As a direct result of advances in therapies available to treat patients with CRPC, treatment decisions have become more complex than ever," said David F. Penson, M.D., M.P.H., chair, department of urologic surgery, Vanderbilt University Medical Center. "TRUMPET will expand our scientific understanding of CRPC to help healthcare professionals, patients and their loved ones make more informed decisions about their care."

TRUMPET is currently enrolling eligible patients and their caregivers; the study will be completed in 2020.

About the TRUMPET Study
TRUMPET (Treatment Registry for Outcomes in CRPC Patients), is a prospective observational registry study designed to better understand the needs and treatment patterns for patients with castration-resistant prostate cancer (CRPC) in the United States. TRUMPET is assessing patient care patterns and does not evaluate any specific treatment or medication.

About Medivation Inc.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of medically innovative therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at www.medivation.com.

About Astellas
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through provision of innovative and reliable pharmaceuticals. For more information on Astellas, please visit our website at www.astellas.us, follow us on Twitter at www.twitter.com/AstellasUS or like our Facebook page at www.facebook.com/AstellasUS.

Contact Information

  • Medivation Contacts
    Rick Bierly
    Chief Financial Officer
    (415) 543-3470

    Anne Bowdidge
    Senior Director, Investor Relations
    (650) 218-6900

    Astellas Contacts
    For Media
    Tyler Marciniak
    Director, Communications and Advocacy
    (847) 736-7145
    Email Contact

    For Investors
    So Sekine
    Associate Manager, Investor Relations
    +81-3-3244-3202
    Email Contact